Hepatosplenic T-Cell Lymphoma · line 1 · CHOEP (cyclophosphamide + doxorubicin + vincristine + etoposide + prednisone), 6 cycles
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-CHOEP |
| ID | IND-HSTCL-1L-CHOEP-UNFIT |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-HSTCL |
| Sources | SRC-ESMO-LYMPHOMA-2025 SRC-NCCN-BCELL-2025 |
Notes
STUB. Fallback when aggressive ICE-allosct pathway unavailable. Expect inferior responses; goals are palliation and transplant bridging if status improves.
Used By
Algorithms
ALGO-HSTCL-1L- ALGO-HSTCL-1L